Antibodies to glutamic acid decarboxylase (GAD) have been associated with a variety of neurological disorders and type 1 diabetes mellitus, and glutamic acid decarboxylase antibodies were first identified in 1988 in patients with type 1 diabetes mellitus and stiff-person syndrome [1]. The gene discussed is GAD1; the disease is type 1 diabetes mellitus.